⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13093541 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL4373616 | 0.98 | — | — | |
| SCHEMBL10250236 | 0.76 | — | — | |
| SCHEMBL7986814 | 0.76 | — | — | |
| SCHEMBL19335038 | 0.76 | — | — | |
| SCHEMBL826310 | 0.76 | — | — | |
| SCHEMBL14470625 | 0.76 | — | — | |
| SCHEMBL5950782 | 0.76 | — | — | |
| SCHEMBL16808523 | 0.76 | — | — | |
| SCHEMBL319924 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | claimed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | claimed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | claimed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | disclosed |
| US-7595336-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2009-09-29 | — | — | US | disclosed |
| US-7282511-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| EP-1442877-B1 | Presensitized lithographic plate comprising microcapsules | FUJIFILM CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | disclosed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | disclosed |
| EP-1255734-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NeuroSearch A/S (DK) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| US-6239128-B1 | COMBATING DISEASES AND DISORDERS ASSOCIATED WITH OR MEDIATED BY THE RELEASE OF EXCITATORY AMINO ACIDS, ASSOCIATED WITH REDUCED BLOOD FLOW TO THE BRAIN AND OTHER CNS TISSUE, | NEUROSEARCH A/S (DK) | 2001-05-29 | — | — | US | disclosed |
| EP-1066037-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES FOR THERAPEUTIC USE | NEUROSEARCH A/S (DK) | 2001-01-10 | — | — | EP | disclosed |
| US-6124285-A | Indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2000-09-26 | — | — | US | disclosed |
| WO-1999049864-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES FOR THERAPEUTIC USE | NEUROSEARCH A/S (DK) | 1999-10-07 | — | — | WO | disclosed |
| EP-0869958-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998014447-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-04-09 | — | — | WO | disclosed |